Update date: Jul 08, 2026 | 120 Pages | Report ID: HO-003241
New Drug CDMO Market
DMA IntelligenceNew Drug CDMO Growth, Trends & Forecast Outlook 2033
Segments: Service (Contract Development, Contract Manufacturing), End Use (Pharmaceutical Companies, Biotech Companies, Others), By Region, And Segment Forecasts
$2075.0M
Market Size, 2025
$2251.4M
Market Estimate, 2026
$3985.3M
Market Forecast, 2033
8.5%
CAGR, 2026–2033
New Drug CDMO Market Size, Share & Key Insights
The New Drug CDMO Market size was valued at USD 2075.00 Million in 2025, and the market is projected to grow from USD 2251.38 Million in 2026 to USD 3985.25 Million by 2033, growing at a CAGR of 8.5% during the forecast period 2026–2033. The market saw distributed global demand in 2025.
Study Overview
 Study Period | 2021 - 2033 |
 Base Year | 2025 |
 Estimated Year | 2026 |
 Forecast Period | 2026-2033 |
 Historical Range | 2021-2025 |
| Units | USD Million |
 Coverage | Global | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
 Deliverables | PDF + Excel Data Pack |
Major Market Players
Key Insights
- The New Drug CDMO market is projected to grow from USD 2075.00 Million in 2025 to USD 3983.90 Million by 2033, demonstrating a robust CAGR of 8.50% over the forecast period, primarily driven by increasing R&D outsourcing.
- North America held the largest market share in 2025, valued at USD 750.00 Million, attributed to significant pharmaceutical R&D investments and a well-established biotechnology sector, while Asia Pacific is anticipated to be the fastest-growing region with a CAGR of 9.5%.
- API Manufacturing is expected to remain the dominant service segment, accounting for a substantial portion of the market revenue, as pharmaceutical companies continue to rely on CDMOs for complex active ingredient production to accelerate drug development timelines.
Market Definition and Strategic Context
The New Drug CDMO Market refers to the contract development and manufacturing services provided to pharmaceutical and biopharmaceutical companies for novel drug candidates, from preclinical development through commercial manufacturing. This encompasses a broad range of activities, including active pharmaceutical ingredient (API) synthesis, formulation development, clinical trial material manufacturing, and commercial drug product manufacturing, along with packaging and labeling services. The market's relevance stems from the increasing complexity of new drug development, the need for specialized expertise, and the growing trend of outsourcing non-core activities to optimize costs and accelerate time-to-market. CDMOs offer significant advantages by providing access to advanced technologies, regulatory knowledge, and scalable manufacturing capabilities, which are crucial for navigating the intricate stages of drug discovery and commercialization. The New Drug CDMO market size was valued at USD 2075.00 Million in 2025 and is poised for substantial industry expansion. The growth outlook for this sector is driven by a robust pipeline of new chemical entities (NCEs) and biologics, increasing R&D investments by pharmaceutical companies, and the strategic shift towards outsourcing to enhance operational efficiency. The market forecast indicates a continued upward trajectory, reflecting the indispensable role CDMOs play in bringing innovative therapies to patients globally. This market is characterized by intense competition among established players and emerging specialists, all striving to offer integrated services and innovative solutions to meet the evolving demands of the pharmaceutical industry. The strategic context highlights a dynamic environment where technological advancements, regulatory changes, and global healthcare needs continually shape the market landscape, influencing service offerings and partnership models. CDMOs are increasingly becoming strategic partners rather than mere service providers, contributing significantly to the overall success of new drug launches.
| Report Attribute | Details |
|---|---|
| Market size value in 2025 | USD 2,075.00 Million |
| Revenue forecast in 2033 | USD 3,985.25 Million |
| Growth rate | CAGR of 8.5% from 2025 to 2033 |
| Actual data | 2021 - 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD Million and CAGR from 2025 to 2033 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Service, End Use |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Argentina; South Africa; UAE; Saudi Arabia; Kuwait; Qatar; Oman |
| Key companies profiled | Catalent, Inc; Lonza; Recipharm AB; Siegfried Holding AG; Patheon Inc; Covance; IQVIA Holdings Inc; Cambrex Corporation; Charles River Laboratories International, Inc; Syneos Health; Syngene International; Jubilant Pharmova; Piramal Pharma Solutions; Dr. Reddy’s CPS; Dishman Carbogen Amcis Ltd; Biocon Biologics; Laurus Labs |
| Customization scope | Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Growth Catalysts & Market Constraints
The New Drug CDMO market is characterized by dynamic forces that significantly influence its growth trajectory and operational landscape. A robust pipeline of new drug candidates, especially in complex therapeutic areas like oncology and rare diseases, acts as a primary growth catalyst, requiring specialized CDMO expertise. The increasing trend of pharmaceutical companies focusing on core competencies and outsourcing manufacturing and development activities further fuels the market's expansion. However, stringent regulatory requirements, high capital investment for advanced manufacturing facilities, and intellectual property concerns pose notable restraints. Despite these challenges, the market continues to present lucrative opportunities through technological advancements in manufacturing processes, bioprocessing, and formulation development. The New Drug CDMO market size is expected to grow steadily, driven by strategic collaborations and geographical expansion into emerging markets. The growth forecast remains optimistic, reflecting the essential role CDMOs play in accelerating drug development and commercialization. Industry expansion is also supported by the rising demand for personalized medicine and biologics, which necessitate flexible and innovative manufacturing solutions. This section delves into the critical drivers, restraints, opportunities, and challenges shaping the New Drug CDMO market, providing a comprehensive understanding of its current and future dynamics.
Growth Drivers
- The burgeoning pipeline of novel drug candidates, particularly biologics and complex small molecules, is a significant driver. Pharmaceutical and biotech companies are increasingly relying on CDMOs for specialized expertise, advanced technologies, and scalable manufacturing capabilities required for these intricate molecules, thereby accelerating their development and market entry.
- A growing preference among pharmaceutical companies to outsource R&D and manufacturing activities is boosting the CDMO market. This strategic shift allows companies to reduce operational costs, access niche technical skills, mitigate risks associated with in-house facility expansion, and focus internal resources on core drug discovery efforts, enhancing overall efficiency.
Restraints
- The high capital expenditure required for establishing and maintaining state-of-the-art manufacturing facilities, especially those compliant with strict regulatory standards (e.g., cGMP), acts as a significant barrier. This substantial investment can limit the entry of new players and constrain the expansion capabilities of smaller CDMOs, impacting market competitiveness.
- Intellectual property (IP) protection concerns and the complexity of technology transfer agreements can restrain market growth. Pharmaceutical companies may be hesitant to fully outsource sensitive processes due to fears of IP leakage or challenges in ensuring seamless integration of proprietary technologies, leading to delays or suboptimal collaboration.
Opportunities
- Advancements in biomanufacturing technologies, such as continuous manufacturing, single-use systems, and automation, present significant opportunities for CDMOs to enhance efficiency, reduce costs, and improve drug quality. Adopting these innovations allows CDMOs to offer more competitive and high-value services, attracting a broader client base and expanding their service portfolio.
- Expansion into emerging markets offers substantial growth potential, driven by rising healthcare expenditures, increasing prevalence of chronic diseases, and growing government support for local pharmaceutical manufacturing. CDMOs can leverage these markets by establishing new facilities or forming strategic partnerships to tap into unmet demands and new client pools.
Challenges
- Intense competition and pricing pressures from a growing number of CDMOs, both global and regional, pose a challenge. Clients often seek cost-effective solutions without compromising quality, forcing CDMOs to continuously optimize their operational efficiencies and pricing strategies, which can impact profit margins.
- Maintaining consistent quality control and ensuring regulatory compliance across diverse geographical regions and complex manufacturing processes is a significant operational challenge. Any deviations can lead to regulatory penalties, reputational damage, and loss of client trust, underscoring the need for robust quality management systems.
Market Level Breakdown
The New Drug CDMO market is comprehensively segmented by Service and End Use, reflecting the diverse operational facets and client bases within the industry. The Service segment encapsulates the core offerings of CDMOs, including API manufacturing, drug product manufacturing, formulation development, and packaging & labeling. API manufacturing typically represents a significant portion due to the complexity and specialized infrastructure required for producing active pharmaceutical ingredients, which are the foundational components of any drug. Drug product manufacturing, involving the conversion of APIs into final dosage forms, also holds a substantial share, driven by the need for advanced facilities and stringent quality control. Formulation development is crucial for optimizing drug efficacy and stability, while packaging & labeling services ensure product integrity and regulatory compliance. Each service plays a critical role in the drug development lifecycle, contributing uniquely to the overall New Drug CDMO market growth and industry expansion.
The End Use segment categorizes the market based on the types of clients utilizing CDMO services, primarily biopharmaceutical companies and pharmaceutical companies. Biopharmaceutical companies are increasingly outsourcing to CDMOs due to the intricate nature of biologics development and manufacturing, which often requires specialized expertise in areas like cell culture, protein purification, and sterile fill-finish. This segment is experiencing rapid growth, driven by the increasing number of biologic drugs in development. Pharmaceutical companies, including both large pharma and smaller biotech firms, also heavily rely on CDMOs for both small molecule and biologic drug development and manufacturing, seeking cost efficiencies, access to advanced technologies, and accelerated timelines. The New Drug CDMO segmentation breakdown highlights how different client needs and drug types drive demand for specific CDMO services, shaping the competitive landscape and strategic focus of market players.
New Drug CDMO Segmentation Breakdown
- Service
- Contract Development
- Contract Manufacturing
- End Use
- Pharmaceutical Companies
- Biotech Companies
- Others
Geographic Performance & Regional Trends
Geographically, North America emerged as the largest market for New Drug CDMO services in 2025, accounting for a significant share of the global revenue. This dominance is primarily attributed to the region's robust pharmaceutical and biotechnology industries, substantial R&D investments, and a high concentration of key market players. The presence of advanced healthcare infrastructure, favorable regulatory environment, and increasing outsourcing trends among large pharmaceutical companies further solidify North America's leading position. Concurrently, Asia Pacific is projected to be the fastest-growing region during the forecast period, driven by expanding pharmaceutical manufacturing capabilities, rising healthcare expenditure, and a growing number of contract research and manufacturing organizations (CROs/CMOs). The region benefits from lower operating costs and a large patient pool, attracting investments from global pharmaceutical giants seeking to leverage its growth potential and contribute to the overall New Drug CDMO market growth.
Regional Growth Drivers
- North America: The region's leadership is underpinned by significant pharmaceutical R&D spending, a high volume of clinical trials, and a strong presence of both established and emerging biopharmaceutical companies. Favorable government initiatives and a robust intellectual property protection framework in the United States and Canada also encourage outsourcing to specialized CDMOs.
- Europe: Growth in Europe is driven by a well-developed pharmaceutical industry, increasing demand for novel therapies, and a strong regulatory framework. Countries like Germany, the United Kingdom, and France benefit from extensive scientific expertise and government funding for life sciences research, fostering a strong CDMO ecosystem.
- Asia Pacific: This region's rapid expansion is fueled by lower manufacturing costs, a large talent pool, and increasing government support for the pharmaceutical and biotechnology sectors. Countries such as China, India, and Japan are becoming attractive hubs for drug development and manufacturing, driving significant investments in CDMO capabilities.
- Latin America: The market in Latin America is propelled by improving healthcare infrastructure, increasing access to advanced medicines, and a rising prevalence of chronic diseases. Brazil and Mexico are key contributors, with growing local pharmaceutical production and efforts to reduce reliance on imported drugs, creating opportunities for CDMOs.
- Middle East & Africa: This region is experiencing growth due to increasing healthcare investments, efforts to diversify economies away from oil, and growing demand for high-quality pharmaceutical products. Countries like Saudi Arabia and the United Arab Emirates are focusing on building local manufacturing capabilities and attracting foreign investment in the pharmaceutical sector.
The future outlook for the New Drug CDMO market indicates a clear distinction between mature and emerging regional trajectories. North America and Europe, while still dominant, are expected to witness steady growth, driven by innovation in complex biologics and personalized medicine. These regions will likely remain centers for high-value, specialized manufacturing. Conversely, Asia Pacific is poised for accelerated expansion, capitalizing on cost advantages, growing local demand, and increasing global pharmaceutical partnerships. Latin America and the Middle East & Africa, though smaller, offer significant untapped potential as healthcare infrastructure improves and outsourcing becomes more prevalent. Strategic implications for suppliers include a need for localized manufacturing capabilities and regulatory expertise in emerging markets, alongside continuous investment in advanced technologies to serve the sophisticated demands of mature regions.
Competitive Insights & Leading Companies
The New Drug CDMO competitive landscape is characterized by a moderately consolidated structure, with a mix of large, integrated global players and specialized regional providers. Global leaders like Catalent, Lonza, and Patheon Inc. offer comprehensive end-to-end services, from drug discovery to commercial manufacturing, leveraging extensive geographical footprints and broad technology platforms. These companies often engage in strategic acquisitions and partnerships to expand their capabilities and market reach. Alongside these giants, numerous mid-sized and niche CDMOs focus on specific therapeutic areas, dosage forms, or technological expertise, carving out their market segments. Competition is intense, driven by factors such as pricing pressures, the need for rapid turnaround times, and the ability to handle complex and highly potent compounds. Key competitive levers include technological innovation, quality and regulatory compliance track records, operational efficiency, and customer service. The market also sees a growing trend of clients seeking integrated service offerings to streamline their drug development processes, putting pressure on CDMOs to continually expand their portfolios and offer seamless solutions. Companies are investing heavily in advanced manufacturing technologies like continuous manufacturing, bioprocessing, and sterile fill-finish capabilities to differentiate themselves and attract pharmaceutical clients. This dynamic environment necessitates continuous adaptation and strategic positioning to maintain a competitive edge in the evolving New Drug CDMO market.
Strategies adopted by leading companies in the New Drug CDMO market primarily revolve around expanding service portfolios, enhancing technological capabilities, and strengthening global presence through organic growth and strategic mergers & acquisitions. Many players are focusing on specialized areas such as high-potency API manufacturing, sterile injectables, and biologics, which command higher margins and require specialized expertise. Product launches and facility expansions are common tactics to increase capacity and cater to growing demand. Differentiation often comes from a strong track record in regulatory approvals, a reputation for quality, and the ability to provide flexible and customized solutions to meet diverse client needs. Companies are also investing in digital transformation and automation to improve efficiency and data integrity across their operations. However, the industry faces challenges such as managing complex global supply chains, ensuring compliance with evolving international regulations, and mitigating the risks associated with intellectual property protection. Margin pressure, especially in generic drug manufacturing, and the high cost of maintaining cutting-edge facilities, further underscore the need for strategic investments and operational excellence. Partnerships with academic institutions and biotech startups are also becoming prevalent to access early-stage innovation and secure future business opportunities, shaping the New Drug CDMO key players' long-term outlook.
New Drug CDMO Key Companies
- Catalent, Inc.
- Lonza
- Recipharm AB
- Siegfried Holding AG
- Patheon Inc.
- Covance
- IQVIA Holdings Inc.
- Cambrex Corporation
- Charles River Laboratories International, Inc.
- Syneos Health
- Syngene International
- Jubilant Pharmova
- Piramal Pharma Solutions
- Dr. Reddy’s CPS
- Dishman Carbogen Amcis Ltd.
- Biocon Biologics
- Laurus Labs
New Drug CDMO Market Ecosystem
Ecosystem Participants
- Pharmaceutical and Biopharmaceutical Companies — These are the primary clients of CDMOs, outsourcing various stages of new drug development and manufacturing. They rely on CDMOs for specialized expertise, advanced facilities, and cost-effective solutions to bring their novel therapies to market faster and more efficiently.
- These companies are responsible for drug discovery and development, often lacking the in-house capacity or specific technological capabilities for large-scale manufacturing or complex formulation, making CDMO partnerships essential for their operational models.
- Contract Development and Manufacturing Organizations (CDMOs) — These organizations provide comprehensive services ranging from preclinical development and clinical trial material production to commercial manufacturing and packaging. They act as strategic partners, offering technical expertise, regulatory guidance, and scalable infrastructure.
- CDMOs differentiate themselves through specialized technologies (e.g., high-potency APIs, sterile injectables), adherence to global quality standards (cGMP), and integrated service offerings that streamline the entire drug lifecycle for their clients.
- Raw Material and Equipment Suppliers — These entities provide the necessary chemicals, excipients, active pharmaceutical ingredients (APIs), and manufacturing equipment to CDMOs. Their role is critical in ensuring the quality, availability, and cost-effectiveness of inputs for drug production.
- Reliable and compliant suppliers are vital for maintaining an uninterrupted supply chain and meeting stringent regulatory requirements, directly impacting the CDMO's ability to deliver high-quality products on schedule.
- Regulatory Bodies and Government Agencies — Organizations like the FDA (U.S.), EMA (Europe), and NMPA (China) establish guidelines and regulations for drug development, manufacturing, and quality control. They play a crucial role in ensuring drug safety and efficacy, overseeing compliance of both pharmaceutical companies and CDMOs.
- Their oversight extends to facility inspections, approval processes for new drugs, and monitoring manufacturing practices, influencing operational standards and technological investments across the CDMO market.
- Research and Academic Institutions — These institutions are often involved in early-stage drug discovery, preclinical research, and developing innovative manufacturing technologies. They collaborate with pharmaceutical companies and CDMOs, contributing to the scientific knowledge base and talent pipeline.
- Such collaborations can accelerate the translation of scientific breakthroughs into viable drug candidates and manufacturing processes, fostering innovation within the broader drug development ecosystem.
- Logistics and Supply Chain Providers — These companies ensure the efficient and compliant transportation, storage, and distribution of raw materials, intermediate products, and finished drug products. They are essential for managing the complex global supply chains inherent in pharmaceutical manufacturing.
- Specialized logistics, including cold chain management and secure transportation for controlled substances, are critical to maintain product integrity and regulatory compliance throughout the distribution network.
Report Coverage & Key Deliverables
The report delivers a comprehensive analysis of the New Drug CDMO, combining quantitative data with qualitative insights. This exhaustive study provides a strategic blueprint for stakeholders, offering an in-depth understanding of market dynamics, competitive landscapes, and future growth opportunities. It meticulously covers historical market performance from 2021 to 2025 and provides a forward-looking forecast up to 2033, enabling businesses to make informed decisions and anticipate market shifts. The report's utility extends to identifying key growth segments, understanding regional market trends, and benchmarking leading players. Decision-makers can leverage this analysis to refine their market entry strategies, optimize product portfolios, and identify potential areas for investment or partnership. The inclusion of both macro and micro-environmental factors ensures a holistic perspective, making it an invaluable resource for pharmaceutical companies, CDMOs, investors, and other industry participants seeking to navigate the complexities of the New Drug CDMO market. The structured presentation of data and insights aims to provide clarity and actionable intelligence, addressing critical business questions and supporting strategic planning across the entire drug development and manufacturing value chain.
Report Coverage
- Market Size Estimates (historical and forecast)
- This section provides detailed market size estimations, covering historical data from 2021 to 2025 and a comprehensive forecast extending to 2033. It includes total market revenue, year-on-year growth rates, and compound annual growth rates (CAGR) for the New Drug CDMO market, offering a robust quantitative foundation for strategic planning and investment analysis.
- Detailed Segmentation And Revenue Analysis
- The report offers an intricate breakdown of the market by key segments, including Service (API Manufacturing, Drug Product Manufacturing, Formulation Development, Packaging & Labeling) and End Use (Biopharmaceutical Companies, Pharmaceutical Companies). Each segment's revenue contribution and growth trajectory are analyzed, providing insights into their market share and future potential within the New Drug CDMO landscape.
- Regional And Country-Level Insights
- A comprehensive regional analysis is provided, covering North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with specific country-level data for major economies. This section highlights regional market dynamics, growth drivers, and challenges, enabling stakeholders to understand market maturity, regulatory environments, and investment opportunities across different geographies.
- Competitive Benchmarking Of Key Players
- This segment offers an in-depth analysis of the competitive landscape, profiling leading New Drug CDMO companies. It includes an overview of their business strategies, product portfolios, recent developments, and market positioning. Competitive benchmarking helps identify key differentiators, strategic alliances, and potential threats within the industry.
- Customization Options Based on Specific Requirements
- Clients can avail customization options to tailor the report content to their specific needs. This includes additional segment breakdowns, deeper country-level analysis, or a focus on particular therapeutic areas or technologies. Our flexible approach ensures that the report provides maximum relevance and value for diverse strategic objectives.
Recent Industry Insights
The New Drug CDMO industry has witnessed a surge of strategic activities and technological advancements over the past 12-18 months, reflecting a dynamic market environment. A notable trend is the increasing number of mergers and acquisitions aimed at expanding service capabilities, geographic reach, and technological expertise. For instance, major CDMOs have acquired smaller, specialized firms to bolster their biologics or high-potency API manufacturing capacity. There's also been a significant focus on digitalization and automation in manufacturing processes to enhance efficiency and data integrity. Regulatory bodies continue to emphasize stringent quality standards and supply chain transparency, prompting CDMOs to invest in advanced quality management systems. Furthermore, the rise of personalized medicine and gene therapies has spurred demand for specialized manufacturing solutions, driving innovation in viral vector production and cell therapy platforms. These New Drug CDMO industry trends indicate a market that is rapidly evolving to meet the complex demands of modern drug development, characterized by continuous innovation and strategic consolidation.
Key Market Developments
- February 2025: Lonza announced a significant expansion of its bioconjugates facility in Switzerland to meet the growing demand for antibody-drug conjugate (ADC) manufacturing services.
- January 2025: Catalent, Inc. completed the acquisition of a specialized sterile fill-finish facility in the United States, enhancing its capacity for complex injectable drug products.
- November 2024: Recipharm AB partnered with a leading biotech firm to provide integrated development and manufacturing services for a new oncology drug candidate, strengthening its position in the European market.
- September 2024: Siegfried Holding AG invested in advanced continuous manufacturing technology at its German site, aiming to improve efficiency and reduce production timelines for small molecule APIs.
- July 2024: Piramal Pharma Solutions expanded its API manufacturing capabilities in India to cater to the increasing demand for highly potent active pharmaceutical ingredients (HPAPIs).
Analyst Opinion
The New Drug CDMO market presents a highly attractive investment proposition, driven by fundamental shifts in the pharmaceutical industry's operating model. The increasing complexity of novel drug molecules, coupled with the capital-intensive nature of advanced manufacturing, compels pharmaceutical and biopharmaceutical companies to increasingly rely on specialized CDMO partners. This trend is expected to continue, ensuring a robust demand pipeline for CDMO services. The competitive intensity is moderately high, with large, integrated players dominating a significant share, while niche providers thrive in specialized segments. Differentiation through technological innovation, strong regulatory compliance, and integrated service offerings is paramount for success. The demand-supply balance currently favors CDMOs with advanced capabilities, particularly in biologics, high-potency APIs, and sterile manufacturing, where capacity constraints are more pronounced. However, as more players invest in these areas, competition is likely to intensify, potentially leading to pricing pressures in certain segments. The New Drug CDMO market outlook remains positive, underpinned by sustained R&D spending and the strategic imperative for pharmaceutical companies to accelerate time-to-market for new therapies.
Looking ahead, the long-term outlook for the New Drug CDMO market is exceptionally promising, with innovation serving as a core driver. Advancements in gene and cell therapies, mRNA technology, and personalized medicine are creating new avenues for CDMOs, requiring highly specialized and flexible manufacturing platforms. Companies that strategically invest in these cutting-edge technologies and develop expertise in complex modalities will be well-positioned for sustained growth. The innovation landscape is also shaped by the adoption of Industry 4.0 principles, including artificial intelligence, machine learning, and advanced analytics, to optimize manufacturing processes and supply chain management. Key risk factors include evolving global regulatory landscapes, which necessitate continuous investment in compliance, and potential supply chain disruptions, as evidenced by recent global events. Furthermore, the ability to attract and retain highly skilled scientific and technical talent remains a critical challenge. Strategic implications for market participants include the need for continuous technological upgrades, a focus on integrated service models, and geographical expansion into high-growth emerging markets to capitalize on the robust New Drug CDMO market outlook and mitigate operational risks effectively.